Bleeding Disorders

Plasma Collection for IVD

Thanks to Mr. Darcy Shannon of Drumlin Plasma, Inc. for the attached SOP, which distinguishes between plasma collected for IVD applications, such as coagulation calibrators, controls, and reagents, and plasma collected to produce therapeutic plasma fractions.

Bleeding Disorders

FVIII-Depleted Reagent Plasma With and Without VWF

The poster, Henneberry S, Rahman M,Wood A, Notini KM, Black KM, Sadeghi-Khomami A. Comparative analysis of commercial factor VIII (FVIII) deficient plasmas with and without von Willebrand factor for FVIII one-stage clotting assay (OSA) was presented on Thursday, 8 May 2025 at the ISLH meeting in Halifax, NS. Click here to see the poster.

Bleeding Disorders

Global Organizations Issue Urgent Call to Action

Click here for the ISTH 6 May 2025 Call to Action: Critical Juncture in Hemophilia Treatment. Thanks to Elaine Benoit, Precision BioLogic Inc. for the heads-up. Please post your comments below. From Bob Gosselin, 7 May 2025: This link is more of a political statement than any notion of gene Rx acceptance treatment in HA […]

Bleeding Disorders

The Choice of Hemophilia Treatments

Here is a brief and informative editorial that lists current hemophilia Rx choices: Makris M, O’Mahony B. Hemophilia treatments and the paradox of choice. Res Pract Thromb Haemost. 2025;9:102726. doi: 10.1016/j.rpth.2025.102726. PMID: 40224276; PMCID: PMC11992418.

Bleeding Disorders

Antithrombin Assay Supports Fitusiran Therapy

Here’s a link to our 1 April 2025 Sanofi announcement about the FDA approval of Fitusiran® therapy. Sanofi provides the Siemens Healthineers’ INNOVANCE Antithrombin® assay, a chromogenic substrate method, as a companion diagnostic tool to support Fitusiran dosing. A Sanofi-supported study compared eight antithrombin activity assay kits on seven coagulometers to indicate the reagent-instrument combinations […]

Bleeding Disorders

More on Rebalancing Therapy: Suppressing Protein S

Click here for your copy of The World Federation of Hemophilia Shared Decision-making Tool, Hemostatic Rebalancing Therapy. We’ve posted several entries about rebalancing therapy… Pfizer’s Hympavzi® (marstacimab) Anti-TFPI Approved Hemophilia Therapeutics Discontinued Fitusiran Approved March 28, 2025 Fitusiran: A “Rebalancing Agent” Concizumab, A “Rebalancing Agent” August 2024 Quick Question Summary: Rebalancing Therapy Alhemo® (concizumab) Rebalancing […]

Bleeding Disorders

Fitusiran Approved March 28, 2025

Thanks to Ali Sadeghi-Khomami, PhD, PBI research scientist, for the following heads-up: On Friday, March 28, 2025, Sanofi Inc. announced the much-awaited approval of fitusiran (Qfitlia®), a “rebalancing” therapeutic that dramatically reduces the ABR in hemophilia A and hemophilia B patients ≥12 YOA with or without inhibitors. Fitusiran is a messenger RNA inhibitor (RNAi) that […]

Bleeding Disorders

Hemophilia Therapeutics Discontinued

Thank you to Elaine Benoit, Precision BioLogic Inc., for this heads-up. Takeda Pharmaceuticals U.S.A. Inc. announced it has discontinued the production of therapeutics HEMOFIL M® and RECOMBINATE®. HEMOFIL M, developed by Baxter Hyland, is a human plasma-derived factor concentrate approved by the US FDA in 1966 for on-demand hemophilia A therapy. RECOMBINATE, also developed by […]

Bleeding Disorders

ASCLS Oregon & Washington Spring Seminar

Click here to access the American Society for Clinical Laboratory Science ASCLS-OR, ASCLS-WA Virtual Spring Seminar, April 3–4, 2025. On Friday, April 4, 8–9 PDT, George presents “Have We Cured Hemophilia?” To download your copy of the presentation handout, click Hemophilia. We look forward to your live attendance for this great two-day program.

Bleeding Disorders

February 2025 Quick Question: FXIII Deficiency

Our February 2025 QQ was a quiz that asked, “What factor deficiency is associated with poor wound healing?” The question attracted 60 participants who answered… FII: 4 (7%) FV: 5 (8%) FVIII: 9 (15%) FIX: 3 (4%) FXIII: 39 (65%) The large majority is correct. Here is the abstract from Luyendyk JP, Flick MJ, Wolberg AS. […]

Bleeding Disorders

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question